Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 6 years of Other Non-Current Liabilities data on file, last reported at $11.1 million in Q4 2024.

• Quarterly Other Non-Current Liabilities rose 1.9% year-over-year to $11.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $11.1 million (up 1.9% YoY) and the FY2024 annual result came in at $11.1 million, up 1.9% from the prior year.
• Other Non-Current Liabilities climbed to $11.1 million in Q4 2024, from $10.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $17.9 million in Q1 2021 to a low of $8.7 million in Q2 2023.
• A 5-year average of $13.7 million and a median of $12.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 162.57% — and 2023, when it sank 46.56%.
• Tracing AUPH's Other Non-Current Liabilities over 5 years: stood at $16.3 million in 2020, then declined by 1.81% to $16.0 million in 2021, then declined by 23.75% to $12.2 million in 2022, then slipped by 10.66% to $10.9 million in 2023, then climbed by 1.9% to $11.1 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $11.1 million (Q4 2024), $10.8 million (Q3 2024), and $10.9 million (Q2 2024), per Business Quant data.